dosReis Susan, Tai Ming-Hui, Camelo Wendy Castillo, Reeves Gloria
Except for Dr. Reeves, the authors are with the Department of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore (e-mail:
Psychiatr Serv. 2016 Oct 1;67(10):1146-1148. doi: 10.1176/appi.ps.201500270. Epub 2016 May 2.
This study aimed to describe state Medicaid psychotropic-monitoring programs targeting youths.
Key informants from each state Medicaid administration and the District of Columbia were invited to participate in a telephone-administered survey designed to assess the implementation strategies of the state psychotropic-monitoring program. Data were collected from August 2011 through December 2012. A total of 38 states participated, four declined, and nine did not respond to the invitation. Descriptive statistics were used to characterize monitoring programs.
Key informants from 28 of the 38 states (74%) reported a program in place, mostly prior authorization (68%). One-third of the programs (32%) had a two-tier review involving pharmacists and child psychiatrists.
Although variability in psychotropic-monitoring programs may limit comparison of program impact across states, the variability provides an opportunity to investigate the impact of different models on best practices and the quality of care.
本研究旨在描述针对青少年的州医疗补助精神药物监测项目。
邀请来自各州医疗补助管理部门以及哥伦比亚特区的关键信息提供者参与一项电话调查,该调查旨在评估州精神药物监测项目的实施策略。数据收集时间为2011年8月至2012年12月。共有38个州参与,4个州拒绝,9个州未回复邀请。采用描述性统计来描述监测项目的特征。
38个州中的28个州(74%)的关键信息提供者报告称有相关项目,多数为预先授权(68%)。三分之一的项目(32%)有药剂师和儿童精神科医生参与的两级审查。
尽管精神药物监测项目的差异可能会限制各州间项目影响的比较,但这种差异为研究不同模式对最佳实践和护理质量的影响提供了机会。